A 52-week, randomized, double-blind phase IIIb trial assessing the efficacy and safety of certolizumab pegol as an add-on therapy to nonbiologic DMARDs in patients with low to moderately active rheumatoid arthritis (RA) showed that addition of certolizumab pegol is effective in this setting, resulting in low disease activity or remission in most patients. However, as remission was not sustained following withdrawal of the drug, the authors recommended that certolizumab pegol be continued in patients achieving remission.